Medical Device Communiqué
|
|
- Roland Carson
- 5 years ago
- Views:
Transcription
1 Medical Device Communiqué Q Demonstrating the Safety of Medical Devices in the Human Body 1 DOJ: The Focus is on GMPs in ROHS II Impacts Medical Device Companies 3 Demonstrating the Safety of Medical Devices in the Human Body UL and the UL logo are trademarks of UL LLC Before approval by the US Food and Drug Administration (FDA), manufacturers of Medical Device and Biopharmaceutical Equipment must demonstrate the safety of their products, not just on the shelf, but when those products interact with the human body. Depending on the degree and duration of their direct contact with the patient, those products must be tested to assess multiple internationally accepted biocompatibility standards. The testing standards are broad and demanding. Testing must assess potential biological hazards, chemical and physical properties and interactions with the human body. Products are also subject to basic microbiological and virology testing; shelf life testing for devices and packaging; and validation of cleaning, reprocessing and sterilization. UL (Underwriters Laboratories) testing services now extend from concept through post-marketing follow-up. UL expanded its testing services to cover the entire product life cycle through its acquisition of MDT (Medical Device Testing GmbH). Germany-based MDT is ISO/IEC accredited and GLP certified. MDT s addition to UL supports the expansion of UL s South Bend laboratory, enabling the company to provide test data confirming both the performance and safety of Medical Devices.
2 DOJ: The Focus is on GMPs in 2013 The US Department of Justice s (DOJ) top areas of focus for 2013 include one area of particular importance to the Medical Device industry. In a speech earlier this year, Maame Ewusi-Mensah Frimpong, Deputy Assistant Attorney General for DOJ s Consumer Protection Branch (CPR) said, We will be taking an especially hard look whenever patients are placed at an unacceptably high risk of harm by violations of current Good Manufacturing Practices. Although Frimpong s statements were aimed at an audience of Pharmaceutical company personnel, her emphasis on Good Manufacturing Practices (GMPs) applies with equal force to companies throughout the Life Science industry. Frimpong offered five recommendations for companies. Those recommendations and corresponding best practices employed by our clients form the topic of an in-depth paper developed by UL Quality, Compliance and Learning. Here is an overview of Frimpong s recommendations and best practices demonstrated by our clients: 1. Make sure the right people are trained in the right topics. Best Practice: automating role-based qualification programs that include seven key elements. 2. Identify and react to problems. Best Practice: build communication touch points into your training program to enable timely quality-related notifications, change control notification, adverse event summary reporting, audit reports and product update notices. 3. Make sure people are satisfied and engaged. Best Practice: integrate quality training and qualification programs with corporate functions including corporate compliance, human resources, sales and marketing, safety education and corporate communication to a strong, cohesive commitment to the company s culture, employees, clients and subcontractors. 4. Ensure that people and policies are working in harmony. Best Practice: clients are using ComplianceWire to electronically capture supervisor observations, employee feedback, production-line performance data, SOP adherence and online quiz results to confirm employee understanding of high-risk SOPs. 5. Gain visibility into what people are doing: Best Practice: scheduling reporting tools giving managers continuous visibility into overall compliance. UL provides practical tools ranging from the ComplianceWire Dashboard; assignment, completion and user reports; advanced reporting tools and audit services. Many Life Science companies Pharmaceutical, Medical Device and Biopharmaceutical have already implemented compliance programs that address key points made by Frimpong. Most companies can do more to ensure consistent compliance responsible to DOJ s 2013 area of focus. Frimpong assured compliance professionals that DOJ recognized many companies had implemented strong compliance programs capable of detecting problems, misconduct and inadequacies before they became criminal offenses and that DOJ s enforcement priorities and approach will recognize those programs in a meaningful way. Page 2
3 ROHS II ImpaCTS medical device COMPanies The original European Directive on the Restriction of the Use of Certain Hazardous Substances in Electrical and Electronic Equipment exempted Medical Devices (RoHS). That changed with the recast of the Directive, now commonly known as RoHS II, which applies to Medical Devices and monitoring and control equipment placed on the European Union market. What RoHS Means for the Industry RoHS restricts the use of certain hazardous substances in designated products in Medical Devices (Category 8) and monitoring and control instruments (Category 9). Medical Devices were exempted under the original RoHS but are required to comply with the RoHS II Directive by July 22, The hazardous substances restricted under RoHS II are: cadmium, hexavalent chromium, lead, mercury and two polybrominated flame retardants. Regulated products are prohibited from containing more than 0.1% by weight of homogenous material (except cadmium, which is limited to 0.01%), meaning that the material cannot be mechanically separated into different materials. RoHS II covers manufacturers, importers and distributors. Note that medical devices are already regulated under the EU s Medical Device Directive (MDD). Compliance with the technical documentation requirements under MDD do not comply with the requirements of RoHS II. Compliance must RoHS II requires companies to provide a Declaration of Conformity. Completing the Declaration involves four steps: 1. Conducting a supplier and material confidence assessment; 2. Collecting supplier declarations, material declarations and analytical test results; 3. Reviewing the information collected for quality and trustworthiness; 4. Conducting ongoing, periodic assessments to ensure the process and output are accurate and current. Page 3
4 Completing the Declaration of Conformity is a complex, time-intensive process that requires a broad range of capabilities and resources. UL provides the services for compliance with RoHS II as well as additional standards that apply to medical devices that may include the MDD, IEC Third Edition, ISO and ISO Services include: Training that covers current restricted substance regulations and the process and documentation requirements of the expanded RoHS II; Gap analysis that assesses processes for risk management and Quality Management Systems. The analysis results in a report that identifies process and procedure gaps to the RoHS II Directive, providing a guide for modifications to existing processes that comply with RoHS II requirements; Review of documents from suppliers to identify any additional information that may be required to demonstrate that all elements are in place to establish due diligence in the supply chain; Analytical testing: UL is an active participant in the IEC Technical Committee, which is responsible for the IEC s international standard for RoHS analytical testing; Ongoing assessments to ensure that production remains in compliance with the RoHS II Directive. This due diligence reflects any changes to materials, parts and subassemblies; Development of technical documentation, quality management systems, and supplier and material assessment processes. Although most medical devices are covered by RoHS II, implantable medical devices are among the electrical and electronic products covered by the Directive. It is important to remember that RoHS II is a CE Mark Directive, meaning that each product covered by the Directive must conduct the necessary technical testing, prepare the accompanying documents and affix the required CE mark to each product. Page 4
5 FDA s EYE on MDR Inadequate Medical Device Reporting (MDR) procedures are in the top five for violations identified by FDA investigators when inspecting Medical Device facilities. Poorly written procedures, insufficient information, late transmission of complete reports to FDA, incomplete documentation, poor training all these failures show up in 483s, Warning Letters and even product recalls. Medical Device companies have good reason to pay attention to the frequency of MDR violations throughout the industry. MDR is just one part of the Food and Drug Administration s Center for Devices and Radiological Health s (CDRH) expanding scrutiny of Medical Device post-market surveillance. Every year, the FDA receives several hundred thousand medical device reports of confirmed or possible device-related serious injuries, deaths and malfunctions. Still, FDA notes, While MDRs are a valuable source of information, this passive surveillance system has notable limitations, including the potential submission of incomplete or inaccurate data, underreporting of events, lack of denominator (exposure) data and the lack of report timeliness. The FDA s September 2012 report, Strengthening Our National System for Medical Device postmarket Surveillance left no doubt about the FDA s focus moving forward. The report proposed a strategy for improving the current system for monitoring the safety and effectiveness of medical devices in the marketplace. FDA s strategy envisions an integrated national medical device postmarket surveillance system that communicates timely and accurate information on the benefits and risks of medical devices; identifies potential safety issues in real-time; reduces the burdens and costs of medical device postmarket surveillance; and facilitates the approval of new devices. Few Medical Device companies would argue with FDA s vision. The value of the strategy, unsurprisingly, lies in the details. In April 2013, FDA attempted to provide some of those details when it issued an update to the September 2012 report. That update describes several initiatives the FDA plans in order to advance its vision of a national postmarket surveillance system. Among the initiatives is the modernization of adverse event reporting and analysis through: Implementation of a mobile application for voluntary adverse event reporting; Piloting an initial functional release of the FDA Adverse Event Reporting System; Implementation of prospective data mining tools in at least three major device areas to enhance identification of highquality adverse event reports and report trends and clusters; Identification of gaps in current methodological efforts to promote data standardization, interoperability, and linkage between registries and disparate data sources. Those initiatives are still in the planning stage. While it s worthwhile for Medical Device companies to understand what the FDA plans for the future, it is even more important for companies to recognize the scrutiny the FDA is applying to MDR procedures in today s facilities. Inadequate MDR systems are likely to remain in the top ten of FDA s inspectional observations. Staying off the FDA s hit list depends on understanding and complying with MDR requirements consistently and thoroughly. Page 5
6 About ul Quality, Compliance and Learning UL Quality, Compliance and Learning is a business line within UL Life & Health s Business Unit. UL is a global independent safety science company offering expertise across five key strategic businesses: Life & Health, Product Safety, Environment, Verification Services and Enterprise Services. UL Quality, Compliance and Learning develops technology-driven solutions to help organizations mitigate risks, improve business performance and establish qualification and training programs through a proprietary, cloud-based platform, ComplianceWire. For more than 30 years, UL has served corporate and government customers in the Life Science, Health Care, Energy and Industrial sectors. Our global quality and compliance management approach integrates ComplianceWire, training content and advisory services, enabling clients to align learning strategies with their quality and compliance objectives. Since 1999, under a unique partnership with the FDA s Office of Regulatory Affairs (ORA), UL Quality, Compliance and Learning has provided the online training, documentation tracking and 21 CFR Part 11-validated platform for ORA-U, the FDA s virtual university. Additionally, UL maintains exclusive partnerships with leading regulatory and industry trade organizations, including AdvaMed, the Drug Information Association, the Personal Care Products Council, and the Duke Clinical Research Institute. Page 6
Addressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics
Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter
More informationLIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies
LIFE SCIENCE 01 BENCHMARKING STUDY Trends and Best Practices Based on Our Work with the US FDA and Over 0 Companies SUMMARY In this report, UL EduNeering has identified the 01/01 compliance and business
More informationComplianceWire. 2012/2013 Benchmarking Study
ComplianceWire 2012/2013 Benchmarking Study ComplianceWire : Life Science 2012/2013 Benchmarking Study Trends and Best Practices Based on the Usage of 250+ Companies Summary Measuring Training to Raise
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationPhoto. Technology s Role in Improving SOP Management Processes
Photo Technology s Role in Improving SOP Management Processes Technology s Role in Improving SOP Management Processes Executive Summary As the industry faces increased globalization, product supply chain
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationPrevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper
Prevent Quality System Deficiencies by Conducting Effective Internal Audits Whitepaper An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management
More informationCOMBINATION PRODUCTS Inspection Readiness and Outcomes
WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews
More informationAAMI Quality Systems White Paper
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,
More informationFDA Initiatives and Regulatory Trends for Life Sciences. Larry Spears President L. Spears Consulting
FDA Initiatives and Regulatory Trends for Life Sciences Larry Spears President L. Spears Consulting Before We Begin If you experience technical problems, please contact GoToMeeting Technical Support at
More informationContents. Regulatory Bodies... 13
Contents UNITED STATES... 3 Regulatory Bodies... 3 Product Classification and Regulatory Control... 3 Application Documents... 3 Quality System Requirements... 4 Product and Manufacturer s License... 4
More informationISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes. Theresa McCarthy
ISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes Theresa McCarthy Welcome and Introductions Please interview and collect: Name Primary Quality Management
More informationDistinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements Draft Guidance for Industry
More informationQuality and Compliance: The Core of the Life Science Learning System
Quality and Compliance: The Core of the Life Science Learning System By Rob Sims, Director, Life Science, UL EduNeering Executive Summary: Quality and Compliance The Core of the Life Science Learning System
More information10 "Must-Haves" for the Life Sciences Learning Management System
10 "Must-Haves" for the Life Sciences Learning Management System Why the Life Sciences LMS Needs to Demonstrate Record Control UL talks to many Life Sciences companies that are exploring learning and development
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More information2013/2014 UL EduNeering ComplianceWire Client Benchmarking Study: Quality Metrics Being Used to Drive Continuous Improvement
2013/2014 UL EduNeering ComplianceWire Client Benchmarking Study: Quality Metrics Being Used to Drive Continuous Improvement UL and the UL logo are trademarks of UL LLC 2013 Agenda About our benchmarking
More informationDisclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
More informationMedical Device Labeling HealthPack 2004 Program
Medical Device Labeling HealthPack 2004 Program Elizabeth Kempen Overview Regulatory Agencies and Pathways Labeling Regulations General Medical Device Labeling Requirements Electronic Labeling FDA s Current
More informationASQ Tappan Zee Section Medical Devices, New Regulations and Standards. 26 th September / V. Fischer / Rev. 01
ASQ Tappan Zee Section Medical Devices, New Regulations and Standards 26 th September / V. Fischer / Rev. 01 Agenda Medical Device, General Aspects Examples Quality System(s) New Regulations & Standards
More informationWhite Paper. Managing Risk in Medical Connectors. Summary. Index. Introduction. About Fischer Connectors
FDA Implementation of IEC 60601-1:2005 Elevates the Responsibilities of Device Developers to New Levels Summary This paper was written to educate those involved with the design and manufacture of medical
More informationGlobal Trends in Audits: Demonstrating Training Effectiveness
Global Trends in Audits: Demonstrating Training Effectiveness UL and the UL logo are trademarks of UL LLC 2013. Agenda Goals for this Discussion Our Panel Industry Audit Trends Our Benchmarking Responses
More informationManaging Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection
Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER
More informationPost market Surveillance ISO EU Medical Device Regulation
Post market Surveillance ISO13485 2016 EU Medical Device Regulation Patrick Caines, Ph.D. Baxter Healthcare 15 June 2017 Agenda Post market Regulatory Requirements ISO 13485 2016 Summary of key changes
More informationKathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration
Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy.Weil@fda.hhs.gov Follow the protocol and IDE regulations
More informationMedical Device Postmarket Compliance in the United States
Articles July 22, 2013 Medical Device Postmarket Compliance in the United States Introduction Once the U.S. Food and Drug Administration (FDA or the agency ) has cleared or approved a medical device for
More informationComplete global Solutions
Complete global Solutions for ELECtro-Medical devices get your product to market faster we know the way 1 sgs medical network THE As a medical devices manufacturer your focus is to create products that
More informationELECtro-Medical devices. in trusted hands. sgs is the world s leading
ELECTRICAL & ELECTRONICS electro MEDICAL DEVICES ELECtro-Medical devices in trusted hands sgs is the world s leading testing and certification company 1 sgs medical network: THE As a medical devices manufacturer
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationMedical Device Single Audit Program (MDSAP) An Overview Canadian Experience
Medical Device Single Audit Program (MDSAP) An Overview Canadian Experience Linda Chatwin Sr. Customer Solutions Consultant : 360-817-5556 : linda.chatwin@ul.com LINDA M CHATWIN, Esq, RAC Biography Ms.
More informationASEPTIC PROCESSING COMPETENCIES
Improving Process and Performance Through ASEPTIC PROCESSING COMPETENCIES UL Aseptic Processing Solutions Solutions that Improve Efficiency & Productivity With regulatory agencies focusing on aseptic processing,
More informationJournal home page: RESEARCH ARTICLE
Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;
More informationGUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES
GUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES Foreword This guidance document is informative and advisory and has no legal authority. Individual national enforcement authorities are bound
More informationPlanning for and Managing FDA Inspections. Focus: 21 CFR, Part 820
Planning for and Managing FDA Inspections Focus: 21 CFR, Part 820 Information, Preventive Action and Strategy 1 The Authority behind Inspections The Safe Medical Devices Act of 1990 (the SMDA), enacted
More informationRE: Docket No. FDA 2017 N 0041: Agency Information Collection Activities; Proposed Collection; Comment Request; Safety Assurance Case
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 7 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2013 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationChoices IEC rd Edition and Component Selection
Choices IEC 60601-1 3rd Edition and Component Selection Choices IEC 60601-1 3rd Edition and Component Selection Abstract When the 3rd edition of IEC 60601-1 was published, it marked the beginning of a
More informationDraft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays
Draft Guidance for Industry, Clinical Laboratories, and FDA Staff In Vitro Diagnostic Multivariate Index Assays DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationThe New EU RoHS Directive: Key Topics Under Review
: Key Topics Under Review Written By: James Calder, Manager Global Services July 6, 2010 Intertek 100-505 March Road, Kanata, ON K2K 3A4 rohs@intertek.com +1 613.599.4321 www.intertek.com/rohs Table of
More informationISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua
ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND
More informationUsing Benefit Risk in Making Post Market Decisions. Adam E Saltman MD PhD Medical Officer, FDA CDRH Office of Compliance AFDO 2018
Using Benefit Risk in Making Post Market Decisions Adam E Saltman MD PhD Medical Officer, FDA CDRH Office of Compliance AFDO 2018 Objectives Understand why FDA is interested in the benefit-risk approach
More informationA REVIEW OF MARKET ENTRY REQUIREMENTS FOR RISK MANAGEMENT, WITH SPECIAL EMPHASIS ON FDA AND ISO COMPLIANCE
BYLINED ARTICLE ON: A REVIEW OF MARKET ENTRY REQUIREMENTS FOR RISK MANAGEMENT, WITH SPECIAL EMPHASIS ON FDA AND ISO 14971 COMPLIANCE By Mark Leimbeck PE Underwriters Laboratories and Larry Kessler Sc.D.
More informationAssuring Food Safety. Presented by Jill Hollingsworth, DVM Vice President, Food Safety Programs
Assuring Food Safety Presented by Jill Hollingsworth, DVM Vice President, Food Safety Programs Advancing American Competitiveness through Conformity Assessment: Legal Issues and Best Practices September
More informationNavigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls
Navigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls Sonali P. Gunawardhana FDA Practice Group Wiley Rein LLP 1776 K Street NW Washington, DC (202) 719-7454 sgunawardhana@wileyrein.com
More informationDemystify Governance, Risk & Compliance For Lifesciences
www.hcltech.com Demystify Governance, Risk & Compliance For Lifesciences Competitive global markets, more-demanding patients, regulations from multiple regulatory authorities and high product development
More informationSoftware Recalls Issues and Challenges
ASQ: Meeting the Compliance Challenge Perspectives from Government, Industry and Quality Professionals: April 28, 2010 Software Recalls Issues and Challenges Jeme Wallace Director Regulatory Affairs GE
More informationKorean Medical Devices Regulations
Korean Devices Regulations The Ministry of Health and Welfare (MHW) is the healthcare agency having overall responsibility for Devices. The Korea Food and Drug Administration (MFDS), an agency under MHW,
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationGMP, GLP OR ISO 17025: HOW DO THESE APPLY TO OUTSOURCED ANALYTICAL TESTING?
GMP, GLP OR ISO 17025: HOW DO THESE APPLY TO OUTSOURCED ANALYTICAL TESTING? Joe Grappin, MS, EAG Laboratories 2018 MD&M West Tech Theater 1 OVERVIEW Background: What Led to the Presentation History of
More informationTable of Contents Adverse Event Reporting SOPs for Medical Devices
Page 2 of 122 Table of Contents Adverse Event Reporting SOPs for Medical Devices Previous Teleconferences About SOPs... 7 Dr. Sharlin's Credentials... 8 Outline Of This Presentation... 9 CDRH Requirements
More informationCopyright GCI, LLC Remediation of Legacy Medical Devices
Copyright GCI, LLC. 2016 Remediation of Legacy Medical Devices Copyright GCI, LLC. 2016 What Drives Legacy Remediation? Proactive Recertification / CE Mark Audit Readiness M&A / Due Diligence Reactive
More informationVoluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program?
Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program? Cisco Vicenty Case for Quality Program Manager Center for Devices and Radiological Health U.S. Food and Drug Administration,
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents
More informationE2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES
E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES PREPARING FOR E2B(R3) T he electronic transmission of adverse event information to stakeholders, using the International Conference on
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationSOFTWARE APPS AS MEDICAL DEVICES. The Regulatory Landscape 2015 WHITE PAPER WHITE PAPER PRODUCED BY MAETRICS
WHITE PAPER SOFTWARE APPS AS MEDICAL DEVICES The Regulatory Landscape 2015 WHITE PAPER PRODUCED BY MAETRICS For more information, please contact: USA Office: +1 317 706 1493 UK Office: +44 115 921 6200
More informationICH Q10/WHO TRS A Regulatory Perspective
Presentation by: Dr. A. Ramkishan Asst. Drugs Controller (India) Govt. of India ICH Q10/WHO TRS A Regulatory Perspective Contents of Presentation Introduction History of WHO GMP TRS guidelines A Unique
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationASTM D10-F02 Workshop FDA Regulatory Perspective. Patrick Weixel FDA Center for Devices and Radiological Health
ASTM D10-F02 Workshop FDA Regulatory Perspective Patrick Weixel FDA Center for Devices and Radiological Health 1 FDA Regulatory Perspective Focus of talk: Use of Standards Auditing Packaging Process Deficiencies
More informationTop Seven Risks to Consider When Selecting a Life Science LMS
Top Seven s to Consider When Selecting a Life Science LMS THE UNINTENDED CONSEQUENCES OF UNINFORMED DECISIONS IN THIS PAPER: Identifying and avoiding gaps in LMS functionality that may lead to critical
More informationMed-Info. Introduction to Korean medical device regulations. TÜV SÜD Product Service GmbH
Med-Info International expert information for the medical device industry Introduction to Korean medical device regulations The Ministry of Food and Drug Safety () is the healthcare agency having overall
More informationfix Menu FDA Pharm 411 Medical Devices Overview of Device Regulations
fix Pharm 411 Medical Devices Overview of Device Regulations Tom Hazlet Pharmaceutical Outcomes Research & Policy Program unique identifiers for medical products & associated billing issues we don t stock
More informationWhite paper Audits in automated production
White paper Audits in automated production data management for automation Introduction: Audits in automated production In the field of production management, audits have become an important tool for analysing
More informationIntroduction to IECQ. Paul Turner April Copyright 2016 BSI. All rights reserved.
Introduction to IECQ Paul Turner April 2016 1 Introduction to Speaker Paul Turner BSI Global Certification Expert Electrical & Gas Business Stream 20 years experience in gas and electrical product certification
More informationThe Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach
The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach CADTH Symposium April 6, 2009 Maurica Maher, MD, MSc Associate Director Office of Legislative
More informationCAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER. ComplianceQuest In-Depth Analysis and Review
CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER ComplianceQuest In-Depth Analysis and Review CAPA Management: Best Practices and FDA QSR Mandate Establishing a corrective and preventive
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationThe SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies
The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies By Rob Sims, UL Compliance to Performance When Life Sciences companies
More informationPHARMACEUTICAL INDUSTRY AND COMPLIANCE. Whitepaper
PHARMACEUTICAL INDUSTRY AND COMPLIANCE Whitepaper Table of Contents Introduction... 2 Compliance: A Critical Consideration... 3 Highly Regulated Environment... 4 Manufacturing Execution Systems (MES)...
More informationMed-Info. Introduction to Korean medical device regulations. TÜV SÜD Product Service GmbH
Med-Info International expert information for the medical device industry Introduction to Korean medical device regulations The Ministry of Food and Drug Safety (MFDS) is the healthcare agency having overall
More informationMark Citriglia Manager of Analytical Services Northeast Ohio Regional Sewer District
Mark Citriglia Manager of Analytical Services Northeast Ohio Regional Sewer District Licensure Non-voluntary process by which a government agency regulates and grants permission for an individual to engage
More informationOctober 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More information(C) QAdvis. IEC and IEC how to make them work (and why so much attention on SW) QAdvis RMD, Prague, November 8th 2016
IEC 62304 and IEC 82304-1 - how to make them work (and why so much attention on SW) QAdvis RMD, Prague, November 8th 2016 QMS in-the cloud Turn key QMS Digital signatures Efficient and lean Validated and
More informationRisk-Based Approach to SAS Program Validation
Paper FC04 Risk-Based Approach to SAS Program Validation Keith C. Benze SEC Associates, Inc. 3900 Paramount Parkway, Suite 150 South Morrisville, NC 27560 ABSTRACT SAS is widely used throughout the FDA
More informationIECQ PUBLICATION QC IEC Quality Assessment System for Electronic Components (IECQ System)
QC 080000 Edition 3.0 2012-05 IECQ PUBLICATION IEC Quality Assessment System for Electronic Components (IECQ System) Hazardous Substance Process Management System Requirements (HSPM) QC 080000:2012(E)
More informationComplianceWire COMPLIANCE MANAGEMENT FOR LIFE SCIENCES ORGANIZATIONS
ComplianceWire COMPLIANCE MANAGEMENT FOR LIFE SCIENCES ORGANIZATIONS COMPLIANCE. PROFICIENCY. PERFORMANCE. ComplianceWire, the best-in-class solution for regulated industries, is a powerful, Part 11 compliant
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationCall: Click: ASRworldwide.com. Reviewing Scope and Non Applicable Sections of ISO 13485:2016 June 2018
Call: 888-891-9002 Click: ASRworldwide.com Reviewing Scope and Non Applicable Sections of ISO 13485:2016 June 2018 Importance of Properly Documented Scope Scope called out in Section 1 of ISO 13485:2016
More informationPresentation Proposal Guidelines
Presentation Proposal Guidelines We are accepting your presentation ideas to share insights, best practices, emerging trends, groundbreaking research and critical industry updates in the area of food safety
More informationUNCONTROLLED DOCUMENT WHEN PRINTED
1. PURPOSE 1.1. The purpose of this procedure is to provide for a system and instructions, and to assign responsibilities for receiving, processing, and investigating customer complaints. 2. APPLICATION
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationCompliant. Connected. Complete. White Paper: SOP Management as a Compliance Tool in FDA and ISO Environments
Compliant. Connected. Complete. : SOP Management as a Compliance Tool in FDA and ISO Environments Introduction From manufacturers to hospitals to the military, most organizations need standard operating
More informationNormative Document on Enterprise Declaration of Conformity on the Pollution Control of Electrical and Electronic Products
Normative Document on Enterprise Declaration of Conformity on the Pollution Control of Electrical and Electronic Products Ministry of Industry and Information Technology May 2012 Page 1 of 8 Normative
More informationCE Marking A short guide to what you need to know about CE Marking
CE Marking A short guide to what you need to know about CE Marking Alastair McLaughlin Product Safety Specialist Slide 1 Who Am I? Name Title: Employer: Alastair McLaughlin Product Safety Specialist Experience:
More informationMedical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS
Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS Key Topics Definitions Essential Principles Classification Conformity Assessment Framework License to Manufacture, Import,
More informationFDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies
ADVISORY February 2011 FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies Contacts On February 15, 2011, the U.S. Food and Drug Administration
More informationPRESENTATION OVERVIEW
Conformance and Interoperability (C&I) Validation Workshop for EAC Region Laico Regency Hotel, Nairobi, Kenya 21st 23rd October 2015 PART 2 Requirements for Accreditation Bodies and Testing Laboratories
More informationLEARNING MANAGEMENT STRATEGY SOLUTIONS
Optimize Your Global Organization s LEARNING MANAGEMENT STRATEGY SOLUTIONS Learning Management Strategy Solutions A Need for Learning Management Performance & Sustainability For many global Life Sciences
More informationUnderstanding the EU Environmental
Understanding the EU Environmental Directives --RoHS (Restriction of Hazardous Substances) --WEEE (Waste of Electrical and Electronic Equipment) --EuP (EcoDesign Requirements for Energy Using Products)
More informationU.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health CDRH STRATEGIC PRIORITIES UPDATE The Center for Devices and Radiological Health
More informationDrug Safety and FDA Revitalization Legislation
Drug Safety and FDA Revitalization Legislation Dan Kracov August 23, 2007 FDA Regulatory and Compliance Symposium House and Senate FDA Revitalization Bills Senate: S. 1082, Food and Drug Administration
More informationScott Gottlieb, MD Commissioner of Food and Drugs Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993
July 31, 2018 Scott Gottlieb, MD Commissioner of Food and Drugs Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Medical Device Safety Action Plan: Protecting Patients,
More informationWHO post-market surveillance of in vitro diagnostics
WHO post-market surveillance of in vitro diagnostics Geneva, 27 November 2015 Anita Sands Prequalification Team World Health Organization About post-market surveillance of IVDs > Some quality, safety and
More informationOVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS Prequalification of Male Circumcision Devices PQMC_007
More informationExternal Defibrillator Improvement Initiative
External Defibrillator Improvement Initiative November 2010 Center for Devices and Radiological Health U.S. Food and Drug Administration External Defibrillator Improvement Initiative Table of Contents
More information